One of the most studied AKT inhibitors, the PI-analogue perifosine, was tested in combination with paclitaxel in a study by Sun et al. [140] demonstrating an increase in ovarian cancer cell apoptosis in the CaOV-3 cell line. The gene discussed is AKT1; the disease is ovarian carcinoma.